April 17th 2024
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
HER2+ Apocrine Carcinoma of the Breast Trends Towards Less Aggressive Phenotype, Favorable Outcomes
April 7th 2022Patients with HER2-positive apocrine carcinoma of the breast are less likely to have an aggressive phenotype and are more likely to have favorable outcomes, even though the group has a lower rate of estrogen and progesterone receptor positivity.